The observed binding to CD200+ B-CLL cells and the reduction in CD200 expression indicates that samalizumab is binding to and blocking its intended target, the immunoregulatory molecule CD200. The gene discussed is CD200; the disease is B-cell chronic lymphocytic leukemia.